Sonire Therapeutics Secures $18M to Advance Pancreatic Cancer Treatment with HIFU Technology
Sonire Therapeutics has raised $18 million in a Series A financing round to advance its High-Intensity Focused Ultrasound (HIFU) therapy system for pancreatic cancer treatment. The funding, led by Santé Ventures, will support the development of Sonire's proprietary non-invasive thermal ablation technology, which offers a safer alternative to traditional surgery or radiation. The device, which has received FDA Breakthrough Device Designation, aims to improve survival rates for pancreatic cancer patients by providing enhanced visualization and outpatient convenience.